Acasti Pharma, Inc. (ACST)

Our attorneys are investigating customer losses in Acasti Pharma, Inc., an investment offered and sold by National Securities Corporation Inc. (NSC) to its retail clients.

If you have suffered losses in Acasti Pharma Inc. , please contact our lawyers for a free and confidential consultation concerning your legal rights and the possibility of recovery.

At Silver Law Group, we know from experience that not every investment recommended and solicited by a stockbroker is suitable and appropriate for the customer. We have seen, particularly in the initial public offering (IPO) space, that investors are often falsely promised high returns and low risk, when in truth the investment is speculative and subject to the loss of principal. Your financial advisor and the securities firm who sells the investment have a legal duty to fully explain the nature of the investment, its inherent risks and the possibility of loss.

Brokers and financial advisors may push risky initial public offerings on unsuspecting investors based upon strong financial incentives, including large commission payouts. Investors in such offerings must realize that these investments are inherently risky and should be considered very carefully before making a decision to invest. Representations made by stockbrokers that such investments are “safe” and “guaranteed” are typically false and are a red flag of possible fraud.

National Securities Corporation Inc. Role in the Investment:

In 2013, National Securities Corporation underwrote Acasti Pharma’s Inc. stock offering. At the close of the offering, National Securities Corporation raised 20 million ($20,000,000). Acasti Pharma, Inc. was listed on the Nasdaq under the stock symbol “ACST”. As of November 14, 2017, Acasti Pharma, Inc. stock is worth $1.27 per share.

Acasti Pharma, Inc. Company Profile:

Acasti Pharma is a biopharmaceutical company working on a potentially cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The corporation’s strategy is to initially develop and commercialize CaPre for the 3 to 4 million patients in the U.S. with severe hypertriglyceridemia. Since its founding in 2008, Acasti Pharma has focused on the market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk.

Silver Law Group represents investment fraud victims in cases to recover their investment losses. If you have questions about your legal rights, please contact Scott Silver of the Silver Law Group for a free consultation at ssilver@silverlaw.com or toll-free at (800) 975-4345.